Asset-Centricity

Asset-centricity is an approach to investing in the life sciences field with a focus on key assets, such as a pharmaceutical molecule that could form the basis for a novel new drug which has already been identified, rather than on discovering such assets through basic research & development.[1][2][3]

The asset-centric investing model is an attempt to streamline the drug discovery process, based on the widely-held belief that it has become too expensive.[2][4] It de-couples life sciences assets from the infrastructure necessary to develop them, with the goal of improving returns on invested capital.[5]

A typical asset-centric startup company would have a single asset, or sometimes two, with a team of experts, including drug developers, shared across a back-end structure and across a variety of portfolio life sciences companies. These team members would coalesce for specific, focused drug-discovery projects[2] The bulk of funding would support the development of the primary asset, with the rest supporting a secondary asset and infrastructure.[1][5][6][7]

History

The asset-centric model of investing was developed by Index Ventures, a venture capital firm.[7][8] Forms of the asset-centric model have subsequently been adopted by other life sciences investment firms such as Atlas Venture and Symphony Capital.[2]

Examples of Asset-Centric companies

Examples of life sciences companies built on the asset-centric investing model include:

References

This article is issued from Wikipedia - version of the Saturday, April 16, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.